// App-Quantinova.ai

587 : Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study

Researchers

Presenter

  • Lung-Ji Chang

Principal Investigators

  • Yu-Chen Liu

  • Yu-Ming Ying

  • Le-Ping Zhang

  • Huyong Zheng

  • Kai Wang

  • Xiao-Li Zheng

  • Heng-Xiang Wang

  • Xun Lai

  • Dong Li

  • Shih-Ting Tsao

  • Ya-Chen Li

  • Li Liu

  • Zhiyong Gao

  • Xiyou Tan

  • Dao-Pei Lu

  • Jian-Ping Zhang

  • Jing-Bo Wang

Medical Centers

  • Department of Hematology, Ming-Ji Hospital, Nanjing, China

  • Hebei Yanda Lu Daopei Hospital, Langfang, China

  • Department of Radiation Oncology, Air Force General Hospital, Beijing, China

  • Department of Radiation Oncology, Air Force General Hospital, Beijing, China

  • Molecular Genetics and Microbioloby, University of Florida, Gainesville, FL

  • Department of Pediatric Hematology, Beijing Children's Hospital, Capital Medical University, Beijing, China

  • Department of Pathology, Peking University Peoples Hospital, Beijing, China

  • BMT Center, Fu Dan University Shanghai Dao-Pei Hospital, Shanghai, China

  • Department of Biomedical Informatics, Biodesign Institute, Arizona State University, Tempe, AZ

  • Department of Gastroenterology, The First Peoples Hospital of Yunnan Province, Kunming, China

  • Shenzhen Genoimmune Medical Institute (GIMI), Shenzhen, China

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved